ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Retrospective Study |
Article Title |
Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Kieron BL Lim, Hamid R Sima, M Isabel Fiel, Viktoriya Khaitova, John T Doucette, Maria Chernyiak, Jawad Ahmad, Nancy Bach, Charissa Chang, Priya Grewal, Leona Kim-Schluger, Lawrence Liu, Joseph Odin, Ponni Perumalswami, Sander S Florman and Thomas D Schiano |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Genentech Pharmaceuticals |
to JTD, in part |
|
Corresponding Author |
Kieron BL Lim, FRCP (Edin), Head, Division of Gastroenterology and Hepatology, National University Centre for Organ Transplantation, National University Hospital, 1E Kent Ridge Road, Tower Block Level 10, Singapore 119228, Singapore. kieron_lim@nuhs.edu.sg |
Key Words |
Hepatitis C recurrence; Liver transplant; Low accelerating dose regimen; Peginterferon α-2a; IL28B |
Core Tip |
This study represents the largest single center experience in treating recurrent hepatitis C virus (HCV) in LT recipients utilizing a low-accelerating-dose regimen (LADR) protocol of PEG alpha-2a and RBV; achieving 38% SVR and superior five-year patient survival in patients with SVR (97% vs 82%, P = 0.001). A novel technique was used to ascertain recipient and donor IL28B (rs12979860) Gt data using archival FFPE tissue from explanted native livers and donor gallbladders. A comprehensive blinded review of available liver histology was performed. LADR strategy remains relevant in managing recurrent HCV where access to DAAs is limited. SVR is associated with improved survival, but fibrosis progression still occurs. |
Publish Date |
2015-05-30 13:32 |
Citation |
Lim KBL, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. World J Gastroenterol 2015; 21(20): 6236-6245 |
URL |
http://www.wjgnet.com/1007-9327/full/v21/i20/6236.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v21.i20.6236 |